已传文件：photo/1773121782.png
The article reported by Wang Hong and Chen Jianwei from Zhejiang University of Technology, if viewed from the perspective of antibacterial materials, the truly remarkable aspect is not merely "another antibacterial drug has been developed", but rather it has successfully integrated three elements: metal antibacterial, specific delivery, and multi-target killing into a complete system. The authors did not simply use bismuth as a broad-spectrum antibacterial metal, but first through systematic developmental genomics, they extracted new iron carrier molecules from Streptomyces, then transformed them into an "iron霉素 that can deceive the iron uptake system of Pseudomonas aeruginosa"， and finally self-assembled them with bismuth citrate into a molecular nanocomplex. That is to say， this is not a simple mixture of "drug + metal"， but an engineered design of a metal antibiotic that actively uses the bacterial iron uptake pathway to enter the cell.
The core information of this abstract can be summarized in one sentence： The authors designed a sideromycin-bismuth synergistic system for Pseudomonas aeruginosa resistant to ciprofloxacin， successfully upgrading the single-target antibiotic into a multi-mechanism antibacterial platform. In the article， after iron霉素7 and bismuth citrate form a 1：1 coordination complex， it mainly kills bacteria through three pathways： first， directly binding to bacterial DNA， causing DNA damage and blocking replication； second， down-regulating KdpC， inhibiting potassium ion transport mediated by KdpFABC， disrupting the osmotic pressure homeostasis； third， inhibiting the oxidative phosphorylation-related complex， resulting in a decrease in ATP production， directly cutting off the bacterial energy metabolism. This means that it does not suppress bacteria through a single point， but acts simultaneously on three levels： genetic material， ion homeostasis， and energy metabolism， making it more difficult for the resistance mechanism to escape quickly.
From the perspective of antibacterial materials， the most notable aspect of this article is that it demonstrates a very strong "design based on the host-pathogen nutrient competition logic". Pseudomonas aeruginosa relies heavily on iron uptake during infection， and the authors precisely seized this point， using iron carrier-like structures to deliver the drug and bismuth "into the cell". The results showed that this synergy was still very strong even in highly resistant bacterial strains， and Fe3+ would competitively weaken its antibacterial effect， indicating that this system indeed utilizes the iron homeostasis pathway to function； at the same time， the increase in bismuth content in the bacteria also proved that it did not blindly spread but achieved relatively precise intracellular enrichment. For those who work on antibacterial biological materials， this strategy is very inspiring： In the future， materials may not only be passively drug release， but also actively hijack the resource uptake system of pathogenic bacteria to improve the killing efficiency.
The related research was published in Cell Reports Medicine under the title "Phylogenomics-driven metalloantibiotic engineering： Overcoming ciprofloxacin resistance in Pseudomonas aeruginosa with sideromycin-bismuth synergy". Associate Professor Chen Jianwei from the School of Pharmacy of Zhejiang University of Technology and doctoral students Pan Jiangwei and Lu Xingyue are the co-first authors； Associate Professor Chen Jianwei from the Marine Drug Team and Professor Wang Hong are the co-corresponding authors.
In 2024， there was also a major sub-press of the element bismuth antibacterial in a field. "Nature Microbiology" broke through the iron barrier： Bismuth-based drugs help antibiotics subdue Pseudomonas aeruginosa
